GI & Endoscopy

Young people, specifically white females, are at a higher risk of contracting rectal cancer and the medical community doesn't know why, Medscape reports.

Takeda announced results from its analysis of real-world data comparing the effectiveness of Entyvio to tumor necrosis factor-alpha antagonist therapy when treating inflammatory bowel disease patients.

Exact Sciences and Rochester, Minn.-based Mayo Clinic researchers are developing a panel using blood-based DNA biomarkers to detect hepatocellular carcinoma.

Moderate-to-severe ulcerative colitis patients treated with mirikizumab, a drug developed by Eli Lilly and Co. to treat autoimmune diseases, achieved significantly greater clinical remission rates at 12 weeks compared to placebo, according to Phase 2 trial results presented at Digestive Disease Week…

Takeda Pharmaceutical Co. acquired 90.83 percent of TiGenix's voting rights through its previously announced takeover effort.

Here are eight updates on GI companies from the past week:

David Lieberman, MD, began his term as the 113th president of the American Gastroenterological Association Institution June 5, at the conclusion of Digestive Disease Week.

The American Society for Gastrointestinal Endoscopy launched a public awareness campaign centered on the link between chronic heartburn and esophageal adenocarcinoma.

Jack Cole, DO, is a gastroenterologist at Greenville, N.C.-based Gastroenterology East.

Pentax Medical entered into distribution agreements with Avantis Medical Systems and CapsoVision.